madchemist
Banned
- Awards
- 0
OUr last response, We have more pressing issues...
I thought I had covered this rather thoroughly but apparently not. You areimplying that using SAR, you can predict not only all pathways, but moreimpressively or actually downright astonishingly, you can predict the oralbioavailability of a compound without it ever being studied, down to a marginof error of 1% apparently with your 0-1% prediction and complete eliminationfrom the body in 3-5 minutes. I have worked in drug discovery and I must say,your ability to do what no one else in history can do places you in an unrealcategory. Pharmaceutical companies would pay you millions atop of millions tobe able to do this. Your accuracy of 99% would put all in silico models toshame. Software developers will be beating down your door with millions andmillions. And who needs animal models any more, they''ll just have you predicteverything.
Structural pro-drugs of dopamine have been thoroughly studied for decades which is why I can say for certainty how these compounds will be metabolized. One of the things you're confused about is the fact that nearly identical analogues have in fact been studied, and dismissed, as recent as 20 years ago. In fact, extremely similar compounds to N-Coumaroyldopamine have made it far in the pharmaceutical pipeline before failing due to kinetic problems - some of the same problems intrinsic to N-Coumaroyldopamine itself. I could literally write a book on how many ways these compounds fail.
It should come as no surprise to anyone that neither of these compounds will be released solo - they will always be packaged into some sort of propriety blend in order to confuse people about their effectiveness (i.e. N-methyltryamine).
I digress. If these compounds are indeed physiologic adrenergic receptor agonists, I challenge you to send a sample either of these phenylpropenic acid derivatives to a few members here (after PA authentication).